Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CameL-Sq
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- NCT03668496 ↗
- Unknown
- Jiangsu HengRui Medicine Co., Ltd.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on CameL-Sq (camrelizumab in first-line stage IV squamous NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CameL-Sq so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized,Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of SHR-1210 in Combination With Carboplatin and Paclitaxel Versus Placebo in Combination With Carboplatin and Paclitaxel in First-Line Stage IV Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Lung Cancer Squamous Cell; Lung Cancer Stage IV; PD-1 Antibody; Chemotherapy Effect
- Interventions
- SHR-1210; The placebo
- Arms
- SHR-1210 +chemotherapy · Experimental
- chemotherapy · Active comparator
- Enrollment
- 390
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Start
- Nov 9, 2018
- Primary completion
- Nov 6, 2020
- Results posted
- No
- Registry record
- NCT03668496 · updated Mar 15, 2021
Publications
linked from the registry- Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol Cancer. 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PubMed 34980131
- Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Yang Z, Shi W, Zou J, Zhou C; CameL-sq Study Group. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16. PubMed 34923163